Ar­ray MEK/BRAF com­bo beats out Roche ri­val in PhI­II melanoma OS show­down

Ar­ray Bio­Phar­ma’s MEK/BRAF in­hibitor com­bo hand­i­ly beat out Roche’s Zelb­o­raf on over­all sur­vival scores among a group of pa­tients suf­fer­ing from ad­vanced melanoma with a BRAF mu­ta­tion.

Al­ready up for re­view at the FDA af­ter post­ing pos­i­tive pro­gres­sion-free sur­vival da­ta, the Boul­der, CO-based com­pa­ny re­port­ed to­day that the com­bi­na­tion of en­co­rafenib 450 mg dai­ly and binime­tinib 45 mg twice dai­ly — dubbed COM­BO450 — pro­duced a me­di­an OS of 33.6 months, dou­bling the 16.9 months record­ed in the Zelb­o­raf (ve­mu­rafinib) arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.